Commercial Space Company Risk / Opportunity Ranking

Thesis: The reviewed sources indicates Kratos has space-defense relevance, including a stated U.S. Space Force/Space Systems Command contract in membership rationale, but there are no retained direct evidence or article summaries within the 90-day recent evidence window to support a current 1 year+ opportunity thesis.

Why now: Why now is weak because no article summaries or direct evidence were retained after the March 29, 2026 cutoff; recency is therefore insufficiently supported in these reviewed sources.

Caveats: Membership rationale references support references and, but no article or retained evidence are provided, so they cannot be cited as factual support under the output rules. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0.

Thesis: No direct positive evidence is retained in the reviewed sources for KVH Industries within the selected recent evidence window.

Why now: The membership rationale says KVH appeared as a listed player in a generic defense satellite communication market report tied to article: but the reviewed sources retains zero evidence after recent evidence window and provides no, so this is too weak for a directional thesis.

Caveats: Generic market-report mention is weaker than company-specific event evidence. The support article ID is cited in the reviewed sources rationale but no article or retained evidence row is provided.

Thesis: The membership rationale indicates LandSpace is a Chinese commercial rocket company pursuing IPO funding and reusable rocket development, but the reviewed sources includes no available within the recent evidence window evidence or article summaries that can support a directional opportunity thesis in this screen.

Why now: Why-now is weak because no within the recent evidence window evidence are available, so timing, financing status, and launch progress cannot be judged from the current reviewed sources.

Caveats: Membership rationale references, and, but no article details are available here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Potential IPO/funding relevance is mentioned only in membership rationale and cannot be elevated without direct evidence.

Thesis: No direct positive evidence is available in the reviewed sources, so no opportunity thesis is supportable.

Why now: The reviewed sources only describes that Intuitive Machines acquired Lanteris for about $800M via article, but provides no available evidence, no business description, and no.

Caveats: Acquisition mention without business detail is insufficient for ranking direction. No post-recent evidence window evidence are available. Referenced has no in the reviewed sources.

Thesis: Reviewed evidence rationale suggests Lonestar is a space data storage startup with a NASA Space Act Agreement and orbital/lunar storage infrastructure, but there is no retained direct positive evidence with article inside the 90-day recent evidence window, so a positive thesis is not currently supportable.

Why now: Why now is weak because 8 articles were considered but zero remained after the March 29, 2026 cutoff, leaving no current catalyst or status confirmation.

Caveats: No recent evidence window-qualified evidence. Phase-2 rationale is not enough for directional conviction.

Thesis: Insufficient retained evidence within the reviewed sources to support a positive 1 year+ opportunity thesis.

Why now: There is no available post-recent evidence window evidence for this company. The reviewed sources notes two considered articles, but zero article IDs after recent evidence window and zero evidence retained, so recency-sensitive judgment is not possible.

Caveats: The reviewed sources say support used article IDs existed earlier, but no retained evidence are available after the 90-day recent evidence window cutoff of March 29, 2026. Absence of evidence is not positive or negative proof.

Thesis: There is a possible long-horizon opportunity if LSS is indeed participating as part of an HPS/LSS consortium building a deployable antenna reflector for a GEO telecommunications satellite, but the reviewed sources provide no available direct evidence inside the 90-day recent evidence window to validate scale, timing, or economics.

Why now: There is no clear 'now' catalyst in the available evidence. The reviewed sources states zero article IDs after recent evidence window and zero evidence available after recent evidence window, so recency is unverified for a 1 year+ ranking.

Caveats: Phase-2 rationale references consortium work tied to: and: but the reviewed sources does not include article summaries or for those items. Coverage debug shows zero evidence after recent evidence window, so no direct claim can be validated as current. Cohort review status is not a directional signal.

Thesis: Lumen Orbit is only described as being mentioned among initiatives related to orbital data centers in an article centered on other companies, which is too weak and indirect to support a positive thesis.

Why now: No dated or citable event evidence is available. The reviewed sources indicates provisional single-article context tied to article id: but no or summary is provided and no evidence survived recent evidence window.

Caveats: Support level is explicitly provisional_single_article_context, which is weaker than company-specific event or fact evidence. No current evidence is provided for article: preventing direct citation. Scores remain minimal due to lack of evidence, not a strong negative view.

Thesis: Reviewed evidence rationale says Lunar Outpost won NASA moon-base or lunar terrain vehicle related work, but no retained article/evidence are available here to substantiate an investable opportunity view.

Why now: There is no retained post-recent evidence window evidence row in these reviewed sources despite membership rationale referencing NASA-related wins, so timing support is insufficient.

Caveats: Membership rationale is not enough for a strong thesis without cited retained evidence. Coverage after recent evidence window is effectively zero in these reviewed sources.

Thesis: Only minimal historical profile-style support is noted for Lunar Outpost as a private company focused on space robotics and lunar surface mobility, but no direct positive evidence survived the 90-day recent evidence window, so there is not enough local evidence to support a substantive 1 year+ opportunity thesis.

Why now: No within the recent evidence window company-specific catalyst or business-state change is available. Coverage debug shows 0 article IDs after recent evidence window and 0 evidence after recent evidence window, with cutoff date March 29, 2026.

Caveats: Reviewed evidence references only a profile-like article via membership rationale, not available direct evidence: but no is provided in these reviewed sources. No current source-cited evidence was found in the reviewed sources.

Thesis: The reviewed sources places M-tron in a 'public space names' market article, but that is thematic basket context rather than direct proof of company-specific opportunity.

Why now: No direct catalyst or citable business-state evidence is available. The reviewed sources references article ids: and: but provides no and no retained evidence.

Caveats: The reviewed sources explicitly says the evidence is mostly thematic/stock-basket context rather than direct business description. No or quotes are provided for direct citation.

Thesis: No positive thesis is supportable from the retained evidence in these reviewed sources. Phase-2 rationale references a partnership with D-Orbit for an electric propulsion demo tied to article, but no representative article, quote, or retained within the recent evidence window evidence row is available here, so the opportunity case cannot be grounded to reviewed sources-standard evidence.

Why now: Why now is weak because the reviewed sources' evidence recent evidence review shows zero kept rows after the 90-day cutoff ending March 29, 2026 and coverage data shows articles after recent evidence window of 0, so recency is not established from retained evidence.

Caveats: Phase-2 membership rationale cites but no or retained evidence row is provided in these reviewed sources, so it cannot be used for factual claims. Coverage after recent evidence window is effectively empty: evidence recent evidence review cutoff_date March 29, 2026 with kept_rows 0. Scores reflect insufficient evidence, not a fundamental bearish or bullish view.

Thesis: No positive thesis is supportable from retained evidence. Phase-2 rationale notes Manastu Space is listed among Indian new-space startups and mentions 'Manastu Space thrusters' tied to article, but the reviewed sources have no representative article or retained evidence row after recent evidence window.

Why now: Why now is weak because no evidence survived the 90-day recent evidence window in the available reviewed sources; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0.

Caveats: Phase-2 rationale is not enough for a factual claim without and retained evidence detail. No within the recent evidence window direct evidence is available. Low scores reflect absence of usable evidence.

Thesis: The membership rationale suggests launch-readiness relevance, but no retained 90-day direct positive evidence is available to support an opportunity thesis.

Why now: The reviewed sources show zero retained article IDs and zero evidence after recent evidence filtering, so there is no recent company-specific evidence base for a 1 year+ directional call.

Caveats: Historical membership support references article IDs, but no post-recent evidence window evidence are served here. Low scores reflect insufficient evidence, not an evaluated business conclusion.

Thesis: The reviewed sources only mentions Marlan Space as an IHC affiliate and partner in the Orbitworks constellation effort, which is context-only and insufficient for a positive thesis without direct company-specific progress evidence.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Marlan Space.

Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. Partnership context alone should not be treated as propagated operating evidence under the evidence standard.

Thesis: There is insufficient direct evidence in the reviewed sources to support an opportunity thesis beyond generic market-report inclusion as a key player in optical satellite markets.

Why now: No 'why now' is evidenced. The reviewed sources show zero post-recent evidence window available evidence despite a large article universe.

Caveats: Phase-2 rationale references: but no or summary is provided. Generic market-report mention is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window.

Thesis: A weak opportunity case exists only because the phase2 rationale says MizarVision images were referenced in a geopolitical article, implying some satellite-imagery relevance. However, the reviewed sources does not provide direct company-specific operating evidence or a citable article summary/.

Why now: No in-recent evidence window article summary or evidence row is available for MizarVision. The only timing cue is an uncited phase2 rationale referencing article id without.

Caveats: Evidence is indirect and not strongly company-specific according to the reviewed sources rationale. No citable article or summary is provided for the referenced article id. No evidence were available after recent evidence window.

Thesis: No affirmative opportunity thesis is supportable from retained evidence. Phase-2 rationale says Moog is cited in a satellite propulsion market report, but no representative article details or retained evidence row is present in the reviewed sources.

Why now: Why now is weak because the reviewed sources have no within the recent evidence window evidence; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0.

Caveats: The lawsuit reference exists only in phase-2 rationale without or retained evidence detail, so it is too weak for a material risk call. No direct evidence arrays are populated. Score reflects limited unresolved risk context plus very sparse evidence.

Thesis: The reviewed sources rationale says Moog supplies components for NASA SLS and is involved in satellite propulsion and components, but no direct positive evidence with article survives the 90-day recent evidence window, so opportunity support is insufficient.

Why now: Why now is weak because despite 72 articles considered, zero article IDs and zero evidence were retained after the March 29, 2026 cutoff, preventing any current sequencing or catalyst assessment.

Caveats: No admissible post-recent evidence window evidence. Membership review rationale is contextual only and not a directional scoring basis by itself.

Thesis: Membership rationale indicates Moonshot Space is developing an electromagnetic accelerator for lunar supplies and that a co-founder invested $6 million, which could support a long-duration moon logistics thesis, but the reviewed sources includes no retained direct evidence or article summaries inside the recent evidence window.

Why now: There is no strong why-now signal because coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window; the cited support article is referenced only in membership rationale without a in the reviewed sources.

Caveats: No article is provided for membership support article, so the underlying factual statements cannot be elevated beyond low-confidence context. No direct positive or direct negative evidence are available after recent evidence window. Long-horizon potential exists, but current reviewed sources support is too thin for a stronger score.

Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation.

Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective.

Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof.

Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives

Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context

Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones.

Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale.

Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026).

Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking

Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking.

Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses.

Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation.

Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement.

Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation.

Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support.

Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at

Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence.

Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk.

Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct.

Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon.

Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources.

Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing.

Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article.

Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high.

Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body.

Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section.

Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress.

Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded.

Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources.

Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty.

Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed.

Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated.

Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables.

Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification.

Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence.

Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded.

Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present.

Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high.

Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows.

Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026).

Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026).

Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation.

Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration.

Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event.

Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain.

Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing.

Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown.